FDA requests boxed warning on gadolinium agents, prompts criticism
This article was originally published in Clinica
Executive Summary
All US FDA-approved gadolinium-based MRI contrast agents (GBMCAs) are to feature a boxed warning on their labelling at the agency's request, to caution physicians about the potential adverse effects of such agents in severe kidney disease patients. The move has prompted mixed reactions from observers. Chairman of the American College of Cardiology (ACR) blue ribbon panel on MR safety, Emanuel Kanal, feels that the FDA's warning request "omits important facts", regarding the higher prevalence of certain agents, notably GE's Omniscan, in causing the debilitating and potentially fatal disease nephrogenic systemic fibrosis (NSF). GBMCAs have now been implicated in over 200 cases of NSF.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.